Physician profile
Perry J Weinstock
NPI 1841396009
$93,569.47
in general payments reported to CMS, 2019-2025
15 companies · $3,499 in 2025
The $3,499 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $7,223 · 2021: $11K · 2022: $12K · 2023: $9,007 · 2024: $8,601 · 2025: $3,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $1,244 · Travel and Lodging: $263 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,585.00 |
| Food and Beverage | $1,244.38 |
| Travel and Lodging | $262.53 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $81,866.62 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $6,989.83 | 2019 | |
| Abbott Laboratories | $2,730.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $1,198.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $221.26 | 2020-2025 | |
| Atricure, INC. | $189.91 | 2022-2023 | |
| Kaneka Medical America LLC | $112.37 | 2019 | |
| Agepha Pharma Fz LLC | $83.75 | 2024 | Lodoco |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.75 | 2019-2023 | Xarelto |
| Pfizer INC. | $23.33 | 2019-2022 | |
| Medicomp INC | $20.21 | 2025 | Telepatch Cardiac Monitor |
| Mirum Pharmaceuticals, INC. | $14.70 | 2025 | Cholbam |
| Boston Scientific Corporation | $13.98 | 2024 | Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $12.72 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Weinstock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.